Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt.
Nephrology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Clin Exp Med. 2022 May;22(2):301-310. doi: 10.1007/s10238-021-00740-w. Epub 2021 Jul 20.
Chronic renal failure patients on dialysis are at a high risk of death due to vascular calcification. This study aimed at investigating the effect of omega-3 fatty acids on the vascular calcification biomarkers fetuin-A and osteoprotegerin (OPG) in patients with chronic renal failure who are undergoing hemodialysis. This prospective, open-label, controlled, parallel study included 60 hemodialysis patients who were randomized to receive either omega-3 fatty acids capsule along with their standard care of treatment (omega-3 group) or their standard care of treatment only (control group). Serum levels of fetuin-A, OPG, calcium, phosphorus, hemoglobin, parathyroid hormone, blood urea nitrogen (BUN), albumin, serum creatinine (SCr), and serum triglycerides (TG) were measured at baseline and after six months of intervention and follow-up of both groups. Significantly increased levels of fetuin-A and OPG (p < 0.001) were observed in the omega-3 group six months after the intervention compared with the control group. Levels of TG, albumin, SCr, BUN, phosphorous, calcium, hemoglobin, and parathyroid hormone were not significantly different in the omega-3 group compared with the control group after six months of intervention. Our study concluded that omega-3 may have a clinically beneficial effect in decreasing cardiovascular events by increasing the levels of the protective vascular calcification inhibitors fetuin-A and osteoprotegerin in chronic renal failure patients who are undergoing hemodialysis.
慢性肾衰竭透析患者由于血管钙化而面临较高的死亡风险。本研究旨在探讨ω-3 脂肪酸对慢性肾衰竭透析患者血管钙化生物标志物胎球蛋白 A 和骨保护素（OPG）的影响。这项前瞻性、开放标签、对照、平行研究纳入了 60 名接受血液透析的患者，他们被随机分为接受ω-3 脂肪酸胶囊加标准治疗（ω-3 组）或仅接受标准治疗（对照组）。在基线和干预后 6 个月以及两组的随访期间，测量了胎球蛋白 A、OPG、钙、磷、血红蛋白、甲状旁腺激素、血尿素氮（BUN）、白蛋白、血清肌酐（SCr）和血清甘油三酯（TG）的水平。与对照组相比，ω-3 组在干预 6 个月后，胎球蛋白 A 和 OPG 的水平显著升高（p<0.001）。与对照组相比，ω-3 组在干预 6 个月后，TG、白蛋白、SCr、BUN、磷、钙、血红蛋白和甲状旁腺激素的水平没有显著差异。本研究得出结论，ω-3 可能通过增加慢性肾衰竭透析患者血管钙化保护抑制剂胎球蛋白 A 和骨保护素的水平，对减少心血管事件产生临床有益的效果。
